

EVOTEC'S TRANSLATIONAL BRIDGE beLAB1407 AWARDS PROJECT FROM DUNDEE UNIVERSITY

- ▶ *PROJECT ORIGINATES FROM DR IGNACIO MORAGA'S LAB AND FOCUSES ON INFLAMMATORY DISORDERS*
- ▶ *BELAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC, BRISTOL MYERS SQUIBB AND UK UNIVERSITIES*

Hamburg, Germany, 01 August 2022:

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb, aiming to accelerate translational research from the UK's academic life science ecosystem.

Building on unique insights into cytokine biology originating from the lab of Dr Ignacio Moraga at the University of Dundee, the selected project will focus on the development of novel biologics for the treatment of inflammatory disorders including inflammatory bowel disease ("IBD"). By promoting the regenerative properties of cytokines while negating the often detrimental inflammatory properties, this method offers a unique approach to treat a variety of conditions. The lab of Dr Mairi McLean at Dundee will provide complimentary expertise in gastrointestinal human tissue organoid cultures.

Using Evotec's integrated discovery and development platform, beLAB1407 will validate the concept of the approach. beLAB1407 was launched in May 2021 as a translational collaboration between Evotec and Bristol Myers Squibb.

Dr Thomas Hanke, EVP & Head of Academic Partnerships at Evotec, commented: "We are delighted to award and fund a Dundee project within the beLAB1407 BRIDGE. After being initiated in 2021, beLAB1407 makes good progress in supporting a portfolio of competitive drug discovery projects and we are pleased to work on the project aiming to resolve chronic autoimmune processes proposed by Dr Ignacio Moraga and his team."

Anne Muir, Head of IP and Commercialisation at University of Dundee

commented: “I am delighted that this first award for Dundee involves the Schools of Life Sciences and Medicine working together. We look forward to more awards from this exciting initiative and to successfully supporting the spinout opportunities that it will enable.”

About Evotec’s BRIDGE model: Partnering to accelerate innovation

Evotec has created a new paradigm to translate early-stage academic research to drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated fund and award framework to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotech. Through these efforts, Evotec has defined a new formula for fast-track early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded a number of different collaborations, e.g. LAB282, LAB150, Autobahn-Labs, Argobio, beLAB2122, beLAB1407, and Danube Labs. Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec’s BRIDGES.

ABOUT EVOTEC SE

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 4,200 highly qualified people. The Company’s 16 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter [@Evotec](https://twitter.com/Evotec) and [LinkedIn](https://www.linkedin.com/company/evotec).

FORWARD-LOOKING STATEMENTS

This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking

statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.